Plain-English translation of NCT06351124 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Crohn's Disease research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether beta-hydroxybutyrate, a natural supplement, can help reduce inflammation in people with Crohn's disease. Researchers want to see if taking this medication alongside standard Crohn's treatments might improve how your body responds and reduce disease activity. The study will also look at how the treatment affects your gut bacteria and inflammation markers.
Current Crohn's treatments help many people, but researchers are looking for additional ways to reduce inflammation and support better outcomes. This medication is being studied because early research suggests it may work with your gut bacteria to help calm inflammation.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would be placed in one of two groups: one group receives standard Crohn's treatment alone, and the other receives standard treatment plus the beta-hydroxybutyrate supplement. Researchers will track changes in your inflammation levels, gut bacteria, and disease symptoms over time through tests and samples. The study is small (about 20 participants total) and is designed to see whether this approach is practical and shows promise before larger research is done.
AI-generated summary from trial data · Jun 17, 2026 · Not medical advice
United States